NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $31.20 +1.25 (+4.17%) Closing price 11/3/2026 04:00 PM EasternExtended Trading$31.22 +0.03 (+0.08%) As of 11/3/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Agios Pharmaceuticals Stock (NASDAQ:AGIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Agios Pharmaceuticals alerts:Sign Up Key Stats Today's Range$30.06▼$31.6450-Day Range$29.95▼$38.1252-Week Range$22.24▼$46.00Volume684,856 shsAverage Volume1.34 million shsMarket Capitalization$1.86 billionP/E RatioN/ADividend YieldN/APrice Target$41.50Consensus RatingModerate Buy Company Overview Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options. Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder. Mitapivat has also been studied in other rare blood disorders, including thalassemia and sickle cell disease. The company was founded in 2008 and initially developed therapies for cancer and rare diseases. In 2021, Agios divested its oncology business to Servier and retained rights to its rare-disease portfolio, allowing it to concentrate on hematology and related metabolic disorders. Agios is headquartered in Cambridge, Massachusetts, and serves patients in the United States and international markets through its commercial operations and partnerships. Brian Goff has served as the company’s chief executive officer since 2023.AI Generated. May Contain Errors. Read More Agios Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreAGIO MarketRank™: 3.55554093182 of 5 starsAgios Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 273rd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 1 strong buy rating, 5 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialAgios Pharmaceuticals has a consensus price target of $41.50, representing about 33.0% upside from its current price of $31.20.Amount of Analyst CoverageAgios Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Agios Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($5.85) to ($4.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -4.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.21% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 1.73%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.61 News SentimentAgios Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Agios Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest3 people have searched for AGIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,285,512.00 in company stock.Percentage Held by Insiders5.40% of the stock of Agios Pharmaceuticals is held by insiders.Percentage Held by InstitutionsAgios Pharmaceuticals has minimal institutional ownership at this time.Read more about Agios Pharmaceuticals' insider trading history. Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGIO Stock News HeadlinesQ3 Earnings Estimate for AGIO Issued By HC WainwrightNovember 2 at 1:14 AM | americanbankingnews.comU.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell DiseaseNovember 1 at 4:04 PM | theglobeandmail.comThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008. | Weiss Ratings (Ad)Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready”November 1 at 4:04 PM | finance.yahoo.comAgios Pharmaceuticals Announces New PDUFA Goal Date For Mitapivat Sickle Cell Disease sNDAOctober 31, 2026 | marketscreener.comMAgios Pharmaceuticals (NASDAQ:AGIO) Stock Picked Up by Analysts at HC WainwrightOctober 31, 2026 | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 7,866 Shares of Company StockOctober 29, 2026 | insidertrades.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock: Insider Sarah Gheuens Sells 500 SharesOctober 24, 2026 | insidertrades.comSee More Headlines AGIO Stock Analysis - Frequently Asked Questions How have AGIO shares performed this year? Agios Pharmaceuticals' stock was trading at $27.22 at the beginning of the year. Since then, AGIO shares have increased by 14.6% and is now trading at $31.20. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by $0.04. The biopharmaceutical company earned $44.75 million during the quarter, compared to analysts' expectations of $26.40 million. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 35.67% and a negative net margin of 418.24%. Read the conference call transcript. When did Agios Pharmaceuticals IPO? Agios Pharmaceuticals (AGIO) raised $88 million in an initial public offering on Wednesday, July 24th 2013. The company issued 5,888,888 shares at $14.00-$16.00 per share. Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (3.16%), Alps Advisors Inc. (0.13%), VIRGINIA RETIREMENT SYSTEMS ET Al (0.05%) and Profund Advisors LLC (0.04%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, Cecilia Jones, Sarah Gheuens, James William Burns, Tsveta Milanova, David Scadden, Kaye I Foster-Cheek, Krishnan Viswanadhan and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA) and NVIDIA (NVDA). Company Calendar Last Earnings7/30/2026Today11/03/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 5 days ago, AGIO's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AGIO CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees540Year Founded2008Price Target and Rating Average Price Target for Agios Pharmaceuticals$41.50 High Price Target$55.00 Low Price Target$32.00 Potential Upside/Downside+33.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($7.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$412.78 million Net Margins-418.24% Pretax Margin-419.27% Return on Equity-35.67% Return on Assets-33.06% Debt Debt-to-Equity RatioN/A Current Ratio10.22 Quick Ratio9.79 Sales & Book Value Annual Sales$54.03 million Price / Sales34.47 Cash FlowN/A Price / Cash FlowN/A Book Value$20.46 per share Price / Book1.52Miscellaneous Outstanding Shares59,700,000Free Float56,478,000Market Cap$1.86 billion OptionableOptionable Beta0.66 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AGIO) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
